Cilengitide, a selective αvβ3 and αvβ5 integrin inhibitor with documented antitumor activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma, did not improve outcomes when combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter in a randomized phase III trial, and will not be developed further as an anticancer drug [587]. Here, MGMT is linked to glioblastoma.